Phase 1/2 Study of NRTX-1001 Neural Cell Therapy in Subjects with Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Return to Grants

Grant Award Details

Grant Number:
CLIN2-13355
Investigator(s):
Institution:
Type:
PI

Human Stem Cell Use:
Award Value:
$7,999,999
Status:
Active

Grant Application Details

Application Title:

Phase 1/2 Study of NRTX-1001 Neural Cell Therapy in Subjects with Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Public Abstract:
Therapeutic Candidate or Device

NRTX-1001 is an inhibitory neuron cell therapy derived from human embryonic stem cells.

Indication

Focal epilepsy; drug-resistant mesial temporal lobe epilepsy.

Therapeutic Mechanism

NRTX-1001 is an inhibitory neuron cell therapy derived from human embryonic stem cells (hESCs) for the prospective treatment of drug-resistant focal epilepsy (MTLE). NRTX-1001 is delivered as a single dose by intracranial injection into the seizure focus, and is intended to distribute locally, functionally integrate, and release the inhibitory neurotransmitter GABA. NRTX-1001 is expected to persist long-term following a single dose and not require repeated administration.


Unmet Medical Need

Current treatments for drug-resistant MTLE include surgical resection and ablation; both are tissue-destructive and can cause serious, irreversible adverse effects. There is a clear need to develop targeted, non-tissue-destructive, and long-lasting therapies that are safe and effective for MTLE.

Project Objective

Initiate/conduct Phase 1; Plan for Phase 2

Major Proposed Activities

  • Initiate and conduct FIH Study of NRTX-1001 in subjects with drug-resistant MTLE (NCT05135091). Includes preclinical and technical support.
  • Clinical operations supporting planning of Stage 2. Includes preclinical and technical support.
Statement of Benefit to California:
Epilepsy affects more than 3 million people in the United States; one-third of epilepsy patients are drug-resistant. Transplantation of inhibitory neuron cell therapy is a novel therapeutic strategy that has shown promise in preclinical studies and could potentially provide a non-tissue-destructive therapeutic option for suppressing seizures in people with drug-resistant focal epilepsy. California medical institutions will participate in the NRTX-1001 clinical trial.